NEWBORN CALF SERUM MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Newborn calf serum is the liquid portion of clotted blood taken from healthy, slaughtered bovine calves younger than 20 days that have been confirmed to be suitable for human consumption. It is widely used in industrial and academic research. It is one of the supplements used as a basal growth medium in cell culture. It plays a major role in stem cell research and the research of veterinary and human vaccines.

Fetal bovine serum and newborn calf serum both contain many of the same nutrients; however, newborn calf serum contains relatively more protein such as albumin and globulins. Bovine calves which are under 14 days old and healthy are inspected and collected for the production of newborn calf serum under strict collection and processing criteria. Newborn calf serum has applications in biotechnology research and development, stem cell research, cloning, animal diagnostic, in vitro fertilization, biopharmaceuticals, gene therapy, synthetic proteins, etc.

Market Dynamics

Increasing collaboration among the market players in order to expand their portfolio is expected to drive the growth of the global newborn calf serum market. For instance, in June 28, 2022, Terumo Blood and Cell Technologies, a medical technology company, collaborated with GenCure, a pharmaceutical company, to expand their manufacturing solutions for cell and gene therapy. The collaboration will utilize expertise from Terumo and GenCure to form a reference manufacturing center for BioBridge Global, provide a wide range of blood, cell and tissue products to customers worldwide. Through this reference site, GenCure will deliver solution for cell and gene therapy developers. Cell and gene therapy uses cell culture techniques and new born calf serum is used for growing different cell lines.

Market players are moving towards advance cell manufacturing technologies, which is expected to drive the global newborn calf serum market growth. For instance, in 2017, the Centre for Advanced Therapeutic Cell Technologies (CATCT) at MaRS, a nonprofit corporation found advanced manufacturing solutions to industrialize the cell manufacturing process to meet the needs of cell therapy companies around the world. Newborn calf serum is key ingredient in growing Vero cell lines, the development of cell manufacturing will increase the use of newborn calf serum.

Conferences have been organized and market players are participating on a large scale for discussion and talking about the rapid development in cell line and cell culture, which is expected to drive the global newborn calf serum market growth. For instance, in 2021, BioProcess International U.S. West conference held virtual event, highlighted its presentation on cell lines stability with different media, boom in cell-line development etc.,  they focused on increasing the awareness among market players about cell culture techniques, through which it is expected the use of calf serum will increase in market.

Key features of the study:

• This report provides an in-depth analysis of the global newborn calf serum market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global newborn calf serum market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include HiMedia Laboratories, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Corning Inc., Atlas Biologicals, Inc., TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., Novus Biologicals, LLC, Capricorn Scientific, PAN biotech, Atlanta Biologicals, Inc., Rockey Mountain Biologicals, GE Healthcare, Serana, and Zhejiang Tianhang Biotechnology.
• Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global newborn calf serum market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global newborn calf serum market

Detailed Segmentation:

• Global Newborn Calf Serum Market, By Origin
  • New Zealand Origin
  • S. Origin
  • Australia Origin
  • Others (Brazil Origin, Mexico Origin, etc.)
• Global Newborn Calf Serum Market, By Application
  • Drug Discovery
  • Cell Media Culture
  • Others
• Global Newborn Calf Serum Market, By End User
  • Biotechnology & Pharmaceutical Industries
  • Academic Institutes
  • Others (Research labs and Diagnostic Labs, etc.)
• Global Newborn Calf Serum Market, By Region
  • North America
    • By country
      • U.S.
      • Canada
  • Latin America
    • By country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By country
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By country
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • HiMedia Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Merck KGaA
  • Corning Inc.
  • Atlas Biologicals, Inc.
  • TCS Biosciences Ltd.
  • Bovogen Biologicals Pty Ltd.
  • Novus Biologicals, LLC
  • Capricorn Scientific
  • PAN biotech
  • Atlanta Biologicals, Inc.
  • Rockey Mountain Biologicals
  • GE Healthcare,
  • Serana,
  • Zhejiang Tianhang Biotechnology.

“*” marked represents similar segmentation in other categories in the respective section.